UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

Annals of oncology, 2013-11, Vol.24 (11), p.2786-2793

2013

Volltextzugriff (PDF)

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Annals of oncology, 2018-12, Vol.29 (12), p.2341-2347

2018

Volltextzugriff (PDF)

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Annals of oncology, 2013-12, Vol.24 (12), p.2978-2984

2013

Volltextzugriff (PDF)

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Annals of oncology, 2015-01, Vol.26 (1), p.95-100

2015

Volltextzugriff (PDF)

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

Breast cancer research and treatment, 2018-02, Vol.168 (1), p.179-187

2018

Volltextzugriff (PDF)

Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study

Annals of oncology, 2007-04, Vol.18 (4), p.689-693

2007

Volltextzugriff (PDF)

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Annals of oncology, 2019-08, Vol.30 (8), p.1279-1288

2019

Volltextzugriff (PDF)

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

Annals of oncology, 2013-09, Vol.24 (9), p.2316-2324

2013

Volltextzugriff (PDF)

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer—comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial

Annals of oncology, 2009-02, Vol.20 (2), p.258-264

2009

Volltextzugriff (PDF)

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

Breast cancer research and treatment, 2017-12, Vol.166 (3), p.775-785

2017

Volltextzugriff (PDF)

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab: a translational project in the neoadjuvant GeparQuinto trial

British journal of cancer, 2012-09, Vol.107 (6), p.956-960

2012

Volltextzugriff (PDF)

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of oncology, 2016-08, Vol.27 (8), p.1519-1525

2016

Volltextzugriff (PDF)

Breast cancer patients' expectations in respect of the physician–patient relationship and treatment management results of a survey of 617 patients

Annals of oncology, 2007-03, Vol.18 (3), p.479-484

2007

Volltextzugriff (PDF)

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

Annals of oncology, 2013-02, Vol.24 (2), p.398-405

2013

Volltextzugriff (PDF)

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

British journal of cancer, 2006-06, Vol.94 (11), p.1615-1620

2006

Volltextzugriff (PDF)

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Annals of oncology, 2017-03, Vol.28 (3), p.497-504

2017

Volltextzugriff (PDF)

Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy

British journal of cancer, 2013-09, Vol.109 (6), p.1528-1536

2013

Volltextzugriff (PDF)

CD44 variant exon epitopes in primary breast cancer and length of survival

The Lancet (British edition), 1995-03, Vol.345 (8950), p.615-619

1995

Volltextzugriff (PDF)

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

Annals of oncology, 2016-06, Vol.27 (6), p.1029-1034

2016

Volltextzugriff (PDF)

Phase II study of gemcitabine in ovarian cancer

Annals of oncology, 1999-07, Vol.10 (7), p.853-855

1999

Volltextzugriff (PDF)

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Annals of oncology, 2016-11, Vol.27 (11), p.2046-2052

2016

Volltextzugriff (PDF)

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)

European journal of cancer (1990), 2016-09, Vol.64, p.12-21

2016

Volltextzugriff (PDF)

Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study

Annals of oncology, 2008-10, Vol.19 (10), p.1698-1705

2008

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(77)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(77)
Female
(76)
Life Sciences & Biomedicine
(72)
Science & Technology
(72)
Oncology
(67)
Adult
(62)
Aged
(57)
Breast Neoplasms - Drug Therapy
(50)
Biological And Medical Sciences
(48)
Medical Sciences
(48)
Tumors
(43)
Breast Cancer
(41)
Breast Neoplasms - Pathology
(38)
Pharmacology. Drug Treatments
(36)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(32)
Antineoplastic Agents
(31)
Gynecology. Andrology. Obstetrics
(30)
Mammary Gland Diseases
(30)
Treatment Outcome
(29)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)

Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy

Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer—comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab: a translational project in the neoadjuvant GeparQuinto trial

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Breast cancer patients' expectations in respect of the physician–patient relationship and treatment management results of a survey of 617 patients

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy

CD44 variant exon epitopes in primary breast cancer and length of survival

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel±darbepoetin alfa in primary breast cancer—results at the time of surgery

Phase II study of gemcitabine in ovarian cancer

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)

Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study

Aktive Filter

Suchergebnisse filtern